Great, another pilot study and another indication where one the RCE antibiotics might be beneficial.
Unfortunately, without a proper phase 2 follow up, one that follows a protocol that the FDA will accept, all these pilots and phase 1 studies are useless and a waste of time and resources.
I'd be much happier if RCE for once selects an indication and proceed with and completes a P2 study. The way things move along (I.e. side ways) at the moment does not help bringing a product to market. Moreover, it eats away from the patent protection period.
Not happy with the current lack of direction
Ann: MCRI Pilot Study- Positive Efficacy Data for Lung Infections, page-4
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.030(5.26%) |
Mkt cap ! $122.3M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 62.0¢ | 56.5¢ | $158.1K | 263.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 77741 | 60.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| RCE (ASX) Chart |